http://www.titanpharm.com/ http://www.titanpharm.com/about http://www.titanpharm.com/about/overview http://www.titanpharm.com/about/management-team http://www.titanpharm.com/about/board-of-directors http://www.titanpharm.com/about/careers http://www.titanpharm.com/news http://www.titanpharm.com/news/overview http://www.titanpharm.com/news/press-releases http://www.titanpharm.com/news/events http://www.titanpharm.com/news/presentations http://www.titanpharm.com/news/in-the-news http://www.titanpharm.com/news/media-resources http://www.titanpharm.com/investors http://www.titanpharm.com/investors/_ http://www.titanpharm.com/investors/news-events http://www.titanpharm.com/investors/news-events/press-releases http://www.titanpharm.com/investors/news-events/ir-calendar http://www.titanpharm.com/investors/news-events/email-alerts http://www.titanpharm.com/investors/company-information http://www.titanpharm.com/investors/company-information/company-information http://www.titanpharm.com/investors/company-information/profile http://www.titanpharm.com/investors/company-information/presentations http://www.titanpharm.com/investors/company-information/management-team http://www.titanpharm.com/investors/company-information/contacts http://www.titanpharm.com/investors/company-information/faq http://www.titanpharm.com/investors/company-information/titan-fcoi-policy http://www.titanpharm.com/investors/sec-filings http://www.titanpharm.com/investors/sec-filings/all-sec-filings http://www.titanpharm.com/investors/sec-filings/annual-reports http://www.titanpharm.com/investors/sec-filings/quarterly-reports http://www.titanpharm.com/investors/sec-filings/section-16-filings http://www.titanpharm.com/investors/corporate-governance http://www.titanpharm.com/investors/corporate-governance/board-of-directors http://www.titanpharm.com/investors/corporate-governance/board-committees http://www.titanpharm.com/investors/corporate-governance/governance-docs http://www.titanpharm.com/contact https://www.titanpharm.com/news/press-releases/detail/277/titan-pharmaceuticals-announces-600000-private-placement-of-convertible-preferred-stock https://www.titanpharm.com/news/press-releases/detail/276/titan-pharmaceuticals-announces-filing-of-registration-statement-for-proposed-business-combination-with-talentec-sdn-bhd https://www.titanpharm.com/news/press-releases/detail/275/titan-pharmaceuticals-announces-1-million-private-placement-of-convertible-preferred-stock https://www.titanpharm.com/news/press-releases/detail/274/titan-pharmaceuticals-inc-announces-receipt-of-notice-from-nasdaq https://www.titanpharm.com/news/press-releases/detail/273/titan-pharmaceuticals-enters-into-merger-agreement-with-ke-sdn-bhd https://www.titanpharm.com/news/press-releases/detail/272/titan-pharmaceuticals-fully-compliant-with-nasdaq-listing-criteria https://www.titanpharm.com/news/press-releases/detail/271/titan-pharmaceuticals-announces-reverse-stock-split-and-ratio https://www.titanpharm.com/news/press-releases/detail/270/titan-pharmaceuticals-announces-appointment-of-dato-seow-gim-shen-and-brynner-chaim-to-the-companys-board-of-directors https://www.titanpharm.com/news/press-releases/detail/269/titan-pharmaceuticals-announces-9-5-million-private-placement-of-convertible-preferred-stock https://www.titanpharm.com/news/press-releases/detail/268/titan-pharmaceuticals-announces-sale-of-certain-proneura-assets https://www.titanpharm.com/news/press-releases/detail/267/titan-pharmaceuticals-provides-shareholder-update https://www.titanpharm.com/news/press-releases/detail/266/update----titan-pharmaceuticals-inc-announces-licensing-agreement-with-ocular-therapeutix-inc https://www.titanpharm.com/news/press-releases/detail/265/titan-pharmaceuticals-announces-board-expansion-and-management-changes https://www.titanpharm.com/news/press-releases/detail/264/titan-pharmaceuticals-announces-fda-clearance-of-ind-application-for-nalmefene-implant https://www.titanpharm.com/news/press-releases/detail/263/titan-pharmaceuticals-announces-pricing-of-5-5-million-registered-direct-and-pipe-offering-priced-at-the-market https://www.titanpharm.com/news/press-releases/detail/262/titan-pharmaceuticals-to-explore-strategic-alternatives https://www.titanpharm.com/news/press-releases/detail/261/sustained-anti-pruritic-effect-of-titans-tp-2021-implant-reported-today-at-neuroscience-2021 https://www.titanpharm.com/news/press-releases/detail/260/titan-announces-upcoming-tp-2021-implant-data-presentation-at-neuroscience-2021 https://www.titanpharm.com/news/press-releases/detail/259/titan-pharmaceuticals-receives-funding-to-develop-combination-hiv-therapeutic-and-contraceptive-implant-for-women-in-developing-countries https://www.titanpharm.com/news/press-releases/detail/258/titan-pharmaceuticals-and-musc-frd-enter-into-research-and-option-license-agreement https://www.titanpharm.com/news/press-releases/detail/257/titan-announces-positive-results-from-the-first-studies-of-tp-2021-implant-in-an-established-animal-model-of-chronic-pruritus https://www.titanpharm.com/news/press-releases/detail/256/titan-pharmaceuticals-announces-filing-of-2020-annual-report-on-form-10-k https://www.titanpharm.com/news/press-releases/detail/255/positive-early-study-results-help-pave-wave-for-titan-pharmaceuticals-to-move-forward-with-its-jt-09-proneura-development-program https://www.titanpharm.com/news/press-releases/detail/254/titan-pharmaceuticals-announces-pricing-of-9-7-million-registered-direct-offering https://www.titanpharm.com/news/press-releases/detail/253/titan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements https://www.titanpharm.com/news/press-releases/detail/252/titan-pharmaceuticals-announces-reverse-stock-split https://www.titanpharm.com/news/press-releases/detail/251/titan-pharmaceuticals-reports-third-quarter-2020-financial-results https://www.titanpharm.com/news/press-releases/detail/250/titan-pharmaceuticals-completes-debt-settlement-with-molteni-and-horizon-acquisiton-of-jt-pharmas-kappa-opioid-agonist-peptide-jt-09 https://www.titanpharm.com/news/press-releases/detail/249/titan-pharmaceuticals-announces-pricing-of-8-0-million-underwritten-public-offering https://www.titanpharm.com/news/press-releases/detail/248/titan-pharmaceuticals-enters-into-definitive-agreement-to-acquire-jt-pharmas-kappa-opioid-agonist-peptide-jt-09 https://www.titanpharm.com/news/press-releases/detail/247/titan-pharmaceuticals-announces-debt-settlement-agreement-with-molteni-and-horizon https://www.titanpharm.com/news/press-releases/detail/246/titan-pharmaceuticals-provides-a-strategic-corporate-update https://www.titanpharm.com/news/press-releases/detail/245/titan-pharmaceuticals-announces-pricing-of-2-7-million-registered-direct-offering https://www.titanpharm.com/news/press-releases/detail/244/titan-pharmaceuticals-stockholders-approve-proposal-to-amend-its-certificate-of-incorporation https://www.titanpharm.com/news/press-releases/detail/243/titans-probuphine-commercialization-partner-molteni-enters-into-exclusive-european-distribution-agreement-with-accord-healthcare https://www.titanpharm.com/news/press-releases/detail/242/titan-pharmaceuticals-provides-update-to-stockholders-on-proposal-to-amend-its-certificate-of-incorporation https://www.titanpharm.com/news/press-releases/detail/241/titan-pharmaceuticals-reports-second-quarter-2020-financial-results https://www.titanpharm.com/news/press-releases/detail/240/titan-pharmaceuticals-to-report-second-quarter-2020-financial-results-on-august-14-2020 https://www.titanpharm.com/news/press-releases/detail/239/titan-pharmaceuticals-urges-stockholders-to-vote-for-proposal-to-amend-its-certificate-of-incorporation https://www.titanpharm.com/news/press-releases/detail/238/titan-pharmaceuticals-and-indegene-enter-into-probuphine-co-promotion-partnership https://www.titanpharm.com/news/press-releases/detail/237/titan-pharmaceuticals-launches-virtual-rems-training-for-probuphine-health-care-providers https://www.titanpharm.com/news/press-releases/detail/236/titan-pharmaceuticals-reports-first-quarter-2020-financial-results https://www.titanpharm.com/news/press-releases/detail/235/titan-pharmaceuticals-to-report-first-quarter-2020-financial-results-on-may-15-2020 https://www.titanpharm.com/news/press-releases/detail/234/titan-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results https://www.titanpharm.com/news/press-releases/detail/233/titan-pharmaceuticals-to-report-fourth-quarter-and-full-year-2019-financial-results-on-march-30-2020 https://www.titanpharm.com/news/press-releases/detail/232/titan-pharmaceuticals-receives-5-9-million-from-exercise-of-warrants https://www.titanpharm.com/news/press-releases/detail/231/titan-pharmaceuticals-announces-addition-of-probuphine-to-federal-supply-schedule https://www.titanpharm.com/news/press-releases/detail/230/titan-pharmaceuticals-announces-pricing-of-2-2-million-registered-direct-offering https://www.titanpharm.com/news/press-releases/detail/229/titan-pharmaceuticals-appoints-dr-kate-devarney-to-its-board-of-directors https://www.titanpharm.com/news/press-releases/detail/228/titan-pharmaceuticals-to-present-at-the-first-annual-biotuesdays-pre-jpm-virtual-conference https://www.titanpharm.com/news/press-releases/detail/227/titan-pharmaceuticals-reports-third-quarter-2019-financial-results https://www.titanpharm.com/news/press-releases/detail/226/titan-pharmaceuticals-to-release-third-quarter-2019-financial-results-on-november-14---conference-call-to-follow https://www.titanpharm.com/news/press-releases/detail/225/titan-pharmaceuticals-to-present-two-posters-on-probuphine-at-the-10th-american-conference-on-pharmacometrics https://www.titanpharm.com/news/press-releases/detail/224/titan-pharmaceuticals-announces-pricing-of-9-0-million-underwritten-public-offering https://www.titanpharm.com/news/press-releases/detail/223/titan-pharmaceuticals-and-crossroads-of-southern-nevada-announce-probuphine-availability-at-crossroads-rehabilitation-facilities https://www.titanpharm.com/news/press-releases/detail/222/titan-receives-approval-for-second-year-of-nida-grant-funding-for-development-of-a-nalmefene-implant https://www.titanpharm.com/news/press-releases/detail/221/titan-pharmaceuticals-reports-second-quarter-2019-financial-results https://www.titanpharm.com/news/press-releases/detail/220/titan-pharmaceuticals-to-release-second-quarter-2019-financial-results-on-august-14---conference-call-to-follow https://www.titanpharm.com/news/press-releases/detail/219/titan-pharmaceuticals-announces-pricing-of-2-1-million-registered-direct-offering https://www.titanpharm.com/news/press-releases/detail/218/titan-pharmaceuticals-expands-patient-access-to-probuphine-via-specialty-product-distribution-agreement-with-cvs-caremark https://www.titanpharm.com/news/press-releases/detail/217/titan-pharmaceuticals-and-molteni-receive-european-regulatory-approval-for-probuphine https://www.titanpharm.com/news/press-releases/detail/216/titan-pharmaceuticals-partners-with-southside-to-further-expand-specialty-pharmacy-network-for-probuphine https://www.titanpharm.com/news/press-releases/detail/215/titan-pharmaceuticals-reports-first-quarter-2019-financial-results https://www.titanpharm.com/news/press-releases/detail/214/titan-pharmaceuticals-further-expands-patient-access-to-probuphine-via-product-purchase-and-supply-agreement-with-express-scripts-specialty-pharmacy-accredo https://www.titanpharm.com/news/press-releases/detail/213/titan-pharmaceuticals-to-release-first-quarter-2019-financial-results-on-may-15---conference-call-to-follow https://www.titanpharm.com/news/press-releases/detail/212/titan-pharmaceuticals-and-molteni-announce-positive-eu-chmp-opinion-for-probuphine https://www.titanpharm.com/news/press-releases/detail/211/c-o-r-r-e-c-t-i-o-n----titan-pharmaceuticals-inc https://www.titanpharm.com/news/press-releases/detail/210/titan-pharmaceuticals-reports-fourth-quarter-and-full-year-2018-financial-results https://www.titanpharm.com/news/press-releases/detail/209/titan-pharmaceuticals-partners-with-appianrx-to-provide-comprehensive-probuphine-patient-support-services https://www.titanpharm.com/news/press-releases/detail/208/titan-pharmaceuticals-to-report-fourth-quarter-and-full-year-2018-financial-results-on-april-1-2019 https://www.titanpharm.com/news/press-releases/detail/207/titan-pharmaceuticals-partners-with-alliancerx-walgreens-prime-specialty-pharmacy-to-expand-patient-access-to-probuphine https://www.titanpharm.com/news/press-releases/detail/206/titan-pharmaceuticals-reports-positive-initial-results-of-probuphine-relaunch https://www.titanpharm.com/news/press-releases/detail/205/titan-pharmaceuticals-announces-reverse-stock-split https://www.titanpharm.com/news/press-releases/detail/204/titan-pharmaceuticals-reports-third-quarter-2018-financial-results https://www.titanpharm.com/news/press-releases/detail/203/titan-pharmaceuticals-schedules-conference-call-to-review-third-quarter-2018-financial-results https://www.titanpharm.com/news/press-releases/detail/202/titan-strengthens-executive-leadership-team-with-appointment-of-chief-commercial-officer https://www.titanpharm.com/news/press-releases/detail/201/titan-pharmaceuticals-prices-9500000-public-offering https://www.titanpharm.com/news/press-releases/detail/200/titan-awarded-nida-grant-for-the-development-of-a-nalmefene-implant-for-the-prevention-of-opioid-addiction-relapse https://www.titanpharm.com/news/press-releases/detail/199/titan-and-the-nevada-center-for-behavioral-health-collaborate-to-evaluate-probuphine-treament-of-oud-patients-within-the-state-of-nevada-criminal-justice-system https://www.titanpharm.com/news/press-releases/detail/198/titan-pharmaceuticals-reports-second-quarter-2018-financial-results https://www.titanpharm.com/news/press-releases/detail/197/titan-announces-amendment-to-agreement-with-molteni https://www.titanpharm.com/news/press-releases/detail/196/titan-pharmaceuticals-provides-update-on-parkinsons-disease-clinical-development-program https://www.titanpharm.com/news/press-releases/detail/195/titan-pharmaceuticals-and-braeburn-announce-mutual-termination-of-license-agreement-for-probuphine-for-opioid-dependence https://www.titanpharm.com/news/press-releases/detail/194/titan-pharmaceuticals-reports-first-quarter-2018-financial-results https://www.titanpharm.com/news/press-releases/detail/193/accomplished-global-pharmaceutical-executive-federico-seghi-recli-appointed-to-titans-board https://www.titanpharm.com/news/press-releases/detail/192/titan-pharmaceuticals-to-report-first-quarter-2018-financial-results-on-may-15-2018 https://www.titanpharm.com/news/press-releases/detail/191/titan-pharmaceuticals-reports-fourth-quarter-and-full-year-2017-financial-results https://www.titanpharm.com/news/press-releases/detail/190/titan-pharmaceuticals-schedules-conference-call-to-review-fourth-quarter-and-full-year-2017-financial-results https://www.titanpharm.com/news/press-releases/detail/189/titan-executes-agreement-for-acquisition-by-molteni-of-probuphine-in-europe-and-other-select-territories https://www.titanpharm.com/news/press-releases/detail/188/titan-announces-amendment-to-horizon-loan-agreement https://www.titanpharm.com/news/press-releases/detail/187/titan-in-discussions-with-braeburn-regarding-u-s-probuphine-commercialization https://www.titanpharm.com/news/press-releases/detail/186/titan-pharmaceuticals-partners-with-molteni-to-market-probuphine-in-europe https://www.titanpharm.com/news/press-releases/detail/185/european-medicines-agency-accepts-titan-pharmaceuticals-marketing-authorization-application-for-probuphine https://www.titanpharm.com/news/press-releases/detail/184/titan-pharmaceuticals-reports-third-quarter-2017-financial-results https://www.titanpharm.com/news/press-releases/detail/183/titan-pharmaceuticals-schedules-conference-call-to-review-third-quarter-2017-financial-results https://www.titanpharm.com/news/press-releases/detail/182/titan-pharmaceuticals-presents-non-clinical-data-from-liothyronine-l-t3-implant-studies https://www.titanpharm.com/news/press-releases/detail/181/first-patient-treated-with-titan-pharmaceuticals-subdermal-implant-for-parkinsons-disease https://www.titanpharm.com/news/press-releases/detail/180/titan-pharmaceuticals-and-opiant-pharmaceuticals-collaborate-to-explore-a-new-approach-to-opioid-use-disorder-treatment https://www.titanpharm.com/news/press-releases/detail/179/titan-pharmaceuticals-to-present-at-cantor-fitzgerald-global-healthcare-conference https://www.titanpharm.com/news/press-releases/detail/178/titan-pharmaceuticals-receives-fda-clearance-to-begin-clinical-study-of-parkinsons-disease-treatment https://www.titanpharm.com/news/press-releases/detail/177/titan-pharmaceuticals-reports-second-quarter-2017-financial-results https://www.titanpharm.com/news/press-releases/detail/176/titan-pharmaceuticals-schedules-conference-call-to-review-second-quarter-2017-financial-results https://www.titanpharm.com/news/press-releases/detail/175/titan-pharmaceuticals-secures-10-million-debt-facility-from-horizon-technology-finance https://www.titanpharm.com/news/press-releases/detail/174/titan-pharmaceuticals-and-walter-reed-army-institute-of-research-collaborate-to-evaluate-proneura-antimalarial-implants https://www.titanpharm.com/news/press-releases/detail/173/fortune-article-highlights-titan-pharmaceuticals-and-its-proneura-technology https://www.titanpharm.com/news/press-releases/detail/172/titan-pharmaceuticals-reports-first-quarter-2017-financial-results https://www.titanpharm.com/news/press-releases/detail/171/titan-pharmaceuticals-schedules-conference-call-to-review-first-quarter-2017-financial-results https://www.titanpharm.com/news/press-releases/detail/170/titan-pharmaceuticals-reports-full-year-and-fourth-quarter-2016-financial-results https://www.titanpharm.com/news/press-releases/detail/169/titan-pharmaceuticals-schedules-conference-call-to-review-fourth-quarter-and-full-year-2016-financial-results https://www.titanpharm.com/news/press-releases/detail/168/titan-pharmaceuticals-to-present-at-29th-annual-roth-conference https://www.titanpharm.com/news/press-releases/detail/167/titan-pharmaceuticals-receives-fda-communication-on-ropinirole-implant-investigational-new-drug-application https://www.titanpharm.com/news/press-releases/detail/166/titan-pharmaceuticals-appoints-two-new-board-members https://www.titanpharm.com/news/press-releases/detail/165/titan-pharmaceuticals-reports-third-quarter-2016-financial-results https://www.titanpharm.com/news/press-releases/detail/164/titan-pharmaceuticals-schedules-conference-call-to-review-third-quarter-2016-financial-results https://www.titanpharm.com/news/press-releases/detail/163/probuphine-implant-for-opioid-dependence-featured-at-2016-international-society-of-addiction-medicine-meeting https://www.titanpharm.com/news/press-releases/detail/162/popular-science-recognizes-probuphine-as-one-of-the-2016-best-of-whats-new https://www.titanpharm.com/news/press-releases/detail/161/titan-pharmaceuticals-reports-second-quarter-2016-financial-results https://www.titanpharm.com/news/press-releases/detail/160/titan-pharmaceuticals-schedules-conference-call-to-review-second-quarter-2016-financial-results https://www.titanpharm.com/news/press-releases/detail/159/titan-pharmaceuticals-added-to-russell-3000-index https://www.titanpharm.com/news/press-releases/detail/158/titan-pharmaceuticals-announces-first-patients-treated-with-probuphiner-for-opioid-dependence https://www.titanpharm.com/news/press-releases/detail/157/titan-pharmaceuticals-announces-rigorous-sensitivity-analyses-confirm-effectiveness-of-probuphiner-for-opioid-dependence https://www.titanpharm.com/news/press-releases/detail/156/titan-pharmaceuticals-receives-15-million-milestone-payment-following-fda-approval-of-probuphiner https://www.titanpharm.com/news/press-releases/detail/155/titan-pharmaceuticals-announces-fda-approval-of-probuphiner-for-the-treatment-of-opioid-dependence https://www.titanpharm.com/news/press-releases/detail/154/titan-pharmaceuticals-reports-first-quarter-2016-financial-results https://www.titanpharm.com/news/press-releases/detail/153/titan-pharmaceuticals-schedules-conference-call-to-review-first-quarter-2016-financial-results https://www.titanpharm.com/news/press-releases/detail/152/titan-pharmaceuticals-announces-presentation-of-probuphine-phase-3-data-at-american-society-of-addiction-medicine-annual-conference https://www.titanpharm.com/news/press-releases/detail/151/titan-pharmaceuticals-reports-full-year-and-fourth-quarter-2015-financial-results https://www.titanpharm.com/news/press-releases/detail/150/titan-pharmaceuticals-to-present-at-28th-annual-roth-conference https://www.titanpharm.com/news/press-releases/detail/149/titan-pharmaceuticals-schedules-conference-call-to-review-fourth-quarter-and-full-year-2015-financial-results https://www.titanpharm.com/news/press-releases/detail/148/titan-pharmaceuticals-receives-feedback-from-fda-on-ropinirole-implant-development-program-for-parkinsons-disease https://www.titanpharm.com/news/press-releases/detail/147/titan-pharmaceuticals-announces-notification-of-fda-action-date-extension-for-probuphine https://www.titanpharm.com/news/press-releases/detail/146/titan-pharmaceuticals-and-braeburn-pharmaceuticals-announce-fda-advisory-committee-recommends-approval-of-probuphine-first-6-month-implant-to-treat-opioid-addiction https://www.titanpharm.com/news/press-releases/detail/145/trading-of-titan-pharmaceuticals-stock-halted-today https://www.titanpharm.com/news/press-releases/detail/144/titan-pharmaceuticals-and-braeburn-pharmaceuticals-announce-date-of-fda-advisory-committee-review-of-probuphine-for-opioid-addiction https://www.titanpharm.com/news/press-releases/detail/143/titan-pharmaceuticals-adds-proneura-implant-for-hypothyroidism-to-product-development-pipeline https://www.titanpharm.com/news/press-releases/detail/142/titan-pharmaceuticals-reports-third-quarter-2015-financial-results https://www.titanpharm.com/news/press-releases/detail/141/titan-pharmaceuticals-schedules-conference-call-to-review-third-quarter-2015-financial-results https://www.titanpharm.com/news/press-releases/detail/140/titan-pharmaceuticals-announces-uplisting-to-nasdaq https://www.titanpharm.com/news/press-releases/detail/139/titan-pharmaceuticals-provides-opinion-of-counsel-covering-issuance-and-resale-of-shares-underlying-public-warrants https://www.titanpharm.com/news/press-releases/detail/138/titan-pharmaceuticals-announces-fdas-acceptance-of-resubmission-of-new-drug-application-for-probuphine https://www.titanpharm.com/news/press-releases/detail/137/titan-pharmaceuticals-announces-reverse-stock-split https://www.titanpharm.com/news/press-releases/detail/136/titan-pharmaceuticals-to-present-at-rodman-renshaw-17th-annual-global-investment-conference https://www.titanpharm.com/news/press-releases/detail/43/titan-pharmaceuticals-announces-resubmission-of-the-new-drug-application-for-probuphine-for-the-maintenance-treatment-of-opioid-addiction https://www.titanpharm.com/news/press-releases/detail/42/titan-pharmaceuticals-reports-second-quarter-2015-financial-results https://www.titanpharm.com/news/press-releases/detail/41/titan-pharmaceuticals-schedules-conference-call-to-review-second-quarter-2015-financial-results https://www.titanpharm.com/news/press-releases/detail/40/titan-pharmaceuticals-presents-nonclinical-data-supporting-use-of-proneura-drug-delivery-platform-in-parkinsons-disease https://www.titanpharm.com/news/press-releases/detail/39/titan-pharmaceuticals-to-present-at-the-bio-international-convention https://www.titanpharm.com/news/press-releases/detail/38/titan-pharmaceuticals-reports-positive-results-from-phase-3-study-of-probuphine-for-opioid-addiction https://www.titanpharm.com/news/press-releases/detail/37/titan-pharmaceuticals-schedules-conference-call-to-review-results-from-phase-3-study-of-probuphine-for-opioid-addiction https://www.titanpharm.com/news/press-releases/detail/36/titan-pharmaceuticals-reports-first-quarter-2015-financial-results https://www.titanpharm.com/news/press-releases/detail/35/titan-pharmaceuticals-schedules-conference-call-to-review-first-quarter-2015-financial-results https://www.titanpharm.com/news/press-releases/detail/34/titan-pharmaceuticals-reports-fourth-quarter-and-full-year-2014-financial-results https://www.titanpharm.com/news/press-releases/detail/24/titan-pharmaceuticals-schedules-conference-call-to-review-fourth-quarter-and-full-year-2014-financial-results https://www.titanpharm.com/news/press-releases/detail/14/titan-pharmaceuticals-to-present-at-27th-annual-roth-conference https://www.titanpharm.com/news/press-releases/detail/135/titan-pharmaceuticals-to-present-at-8th-annual-onemedforum https://www.titanpharm.com/news/press-releases/detail/134/titan-pharmaceuticals-to-present-at-ld-micro-conference https://www.titanpharm.com/news/press-releases/detail/133/titan-pharmaceuticals-announces-completion-of-enrollment-in-phase-3-study-of-probuphine-for-opioid-dependence https://www.titanpharm.com/news/press-releases/detail/132/titan-pharmaceuticals-announces-third-quarter-2014-financial-results https://www.titanpharm.com/news/press-releases/detail/131/titan-pharmaceuticals-appoints-two-new-board-members https://www.titanpharm.com/news/press-releases/detail/130/titan-pharmaceuticals-schedules-conference-call-to-review-third-quarter-2014-financial-results https://www.titanpharm.com/news/press-releases/detail/129/titan-pharmaceuticals-announces-pricing-of-public-offering https://www.titanpharm.com/news/press-releases/detail/128/titan-pharmaceuticals-announces-enrollment-reaches-halfway-mark-in-phase-3-study-of-probuphine-for-opioid-dependence https://www.titanpharm.com/news/press-releases/detail/127/titan-pharmaceuticals-to-present-at-rodman-renshaw-16th-annual-global-investment-conference https://www.titanpharm.com/news/press-releases/detail/126/titan-pharmaceuticals-announces-second-quarter-2014-financial-results https://www.titanpharm.com/news/press-releases/detail/125/titan-pharmaceuticals-schedules-conference-call-to-review-second-quarter-2014-financial-results https://www.titanpharm.com/news/press-releases/detail/124/titan-pharmaceuticals-announces-first-patient-enrollment-in-clinical-study-of-probuphine-for-opioid-dependence https://www.titanpharm.com/news/press-releases/detail/123/titan-pharmaceuticals-announces-first-quarter-2014-financial-results https://www.titanpharm.com/news/press-releases/detail/122/titan-pharmaceuticals-schedules-conference-call-to-review-first-quarter-2014-financial-results https://www.titanpharm.com/news/press-releases/detail/121/titan-pharmaceuticals-provides-overview-of-upcoming-clinical-study-of-probuphine-following-clear-guidance-from-the-fda https://www.titanpharm.com/news/press-releases/detail/120/titan-pharmaceuticals-announces-fourth-quarter-and-year-end-2013-financial-results https://www.titanpharm.com/news/press-releases/detail/119/titan-pharmaceuticals-schedules-conference-call-to-review-fourth-quarter-and-full-year-2013-financial-results https://www.titanpharm.com/news/press-releases/detail/118/titan-pharmaceuticals-announces-agreement-in-principle-on-path-forward-for-probuphine-clinical-study https://www.titanpharm.com/news/press-releases/detail/117/titan-pharmaceuticals-receives-official-minutes-from-fda-meeting-on-probuphine-new-drug-application https://www.titanpharm.com/news/press-releases/detail/116/titan-pharmaceuticals-announces-third-quarter-2013-financial-results https://www.titanpharm.com/news/press-releases/detail/115/titan-pharmaceuticals-announces-5-million-equity-investment-and-restructuring-of-probuphine-partnership https://www.titanpharm.com/news/press-releases/detail/114/titan-pharmaceuticals-schedules-conference-call-to-review-third-quarter-2013-financial-results https://www.titanpharm.com/news/press-releases/detail/113/titan-pharmaceuticals-announces-confirmation-of-meeting-with-fda-regarding-probuphine https://www.titanpharm.com/news/press-releases/detail/112/titan-pharmaceuticals-announces-submission-of-fda-meeting-request-regarding-probuphine https://www.titanpharm.com/news/press-releases/detail/111/titan-pharmaceuticals-announces-second-quarter-2013-financial-results https://www.titanpharm.com/news/press-releases/detail/110/titan-pharmaceuticals-announces-publication-of-phase-3-probuphine-data-in-addiction https://www.titanpharm.com/news/press-releases/detail/109/titan-pharmaceuticals-schedules-conference-call-to-review-second-quarter-2013-financial-results https://www.titanpharm.com/news/press-releases/detail/108/titan-pharmaceuticals-announces-amendment-to-partnership-with-braeburn-pharmaceuticals https://www.titanpharm.com/news/press-releases/detail/107/titan-pharmaceuticals-announces-first-quarter-2013-financial-results https://www.titanpharm.com/news/press-releases/detail/106/titan-pharmaceuticals-announces-first-quarter-2013-financial-results https://www.titanpharm.com/news/press-releases/detail/105/titan-pharmaceuticals-schedules-conference-call-to-review-first-quarter-2013-financial-results https://www.titanpharm.com/news/press-releases/detail/104/titan-pharmaceuticals-receives-complete-response-letter-from-the-fda-for-probuphine-new-drug-application https://www.titanpharm.com/news/press-releases/detail/103/titan-pharmaceuticals-probuphine-program-to-be-presented-at-asam-medical-scientific-conference-and-apa-annual-meeting https://www.titanpharm.com/news/press-releases/detail/102/titan-pharmaceuticals-announces-fda-advisory-committee-recommends-approval-of-probuphine-for-the-treatment-of-adult-patients-with-opioid-dependence https://www.titanpharm.com/news/press-releases/detail/101/titan-pharmaceuticals-announces-fourth-quarter-and-year-end-2012-financial-results https://www.titanpharm.com/news/press-releases/detail/100/titan-pharmaceuticals-schedules-conference-call-to-review-fourth-quarter-and-full-year-2012-financial-results https://www.titanpharm.com/news/press-releases/detail/99/titan-pharmaceuticals-announces-date-of-fda-advisory-committee-review-of-probuphiner-for-the-treatment-of-opioid-dependence https://www.titanpharm.com/news/press-releases/detail/98/probuphiner-receives-fda-priority-review-designation-for-adult-patients-with-opioid-dependence https://www.titanpharm.com/news/press-releases/detail/97/titan-pharmaceuticals-licenses-exclusive-probuphiner-commercialization-rights-in-u-s-and-canada-to-braeburn-pharmaceuticals https://www.titanpharm.com/news/press-releases/detail/96/titan-pharmaceuticals-announces-third-quarter-2012-financial-results https://www.titanpharm.com/news/press-releases/detail/95/titan-pharmaceuticals-announces-4-25-million-stock-purchase-and-option-agreement https://www.titanpharm.com/news/press-releases/detail/94/titan-pharmaceuticals-announces-second-quarter-2012-financial-results https://www.titanpharm.com/news/press-releases/detail/93/titan-pharmaceuticals-schedules-conference-call-to-review-second-quarter-2012-financial-results https://www.titanpharm.com/news/press-releases/detail/92/titan-completes-preclinical-study-of-a-continuous-dopamine-agonist-treatment-for-parkinsons-disease https://www.titanpharm.com/news/press-releases/detail/91/titan-pharmaceuticals-announces-first-quarter-2012-financial-results https://www.titanpharm.com/news/press-releases/detail/90/titan-pharmaceuticals-schedules-conference-call-to-review-first-quarter-2012-financial-results https://www.titanpharm.com/news/press-releases/detail/89/titan-pharmaceuticals-announces-phase-3-probuphiner-data-presentation-at-the-american-society-of-addiction-medicine-asam-43rd-medical-scientific-conference https://www.titanpharm.com/news/press-releases/detail/88/titan-pharmaceuticals-to-raise-5-5-million-in-registered-direct-offering https://www.titanpharm.com/news/press-releases/detail/87/titan-pharmaceuticals-announces-fourth-quarter-and-year-end-2011-financial-results https://www.titanpharm.com/news/press-releases/detail/86/titan-pharmaceuticals-schedules-conference-call-to-review-fourth-quarter-and-full-year-2011-financial-results https://www.titanpharm.com/news/press-releases/detail/85/titan-pharmaceuticals-to-participate-in-rbc-capital-markets-global-healthcare-conference https://www.titanpharm.com/news/press-releases/detail/84/titan-pharmaceuticals-announces-positive-results-of-six-month-open-label-safety-retreatment-study-of-probuphine https://www.titanpharm.com/news/press-releases/detail/83/titan-pharmaceuticals-to-present-at-14th-annual-bio-ceo-investor-conference https://www.titanpharm.com/news/press-releases/detail/82/titan-pharmaceuticals-adopts-stockholder-rights-plan-files-shelf-registration-of-securities-on-form-s-3 https://www.titanpharm.com/news/press-releases/detail/81/titan-pharmaceuticals-confirms-regulatory-guidance-for-probuphine https://www.titanpharm.com/news/press-releases/detail/80/titan-pharmaceuticals-announces-probuphine-presentation-at-american-society-of-addiction-medicine-conference https://www.titanpharm.com/news/press-releases/detail/79/titan-pharmaceuticals-announces-second-quarter-2011-financial-results https://www.titanpharm.com/news/press-releases/detail/78/titan-pharmaceuticals-provides-additional-positive-results-in-confirmatory-phase-3-trial-of-probuphine https://www.titanpharm.com/news/press-releases/detail/77/titan-pharmaceuticals-schedules-conference-call-to-review-second-quarter-2011-financial-results-and-probuphine-phase-3-clinical-study-results https://www.titanpharm.com/news/press-releases/detail/76/titan-pharmaceuticals-announces-positive-top-line-results-in-confirmatory-phase-3-trial-of-probuphine https://www.titanpharm.com/news/press-releases/detail/75/titan-pharmaceuticals-provides-update-on-confirmatory-phase-3-study-of-probuphine https://www.titanpharm.com/news/press-releases/detail/74/titan-pharmaceuticals-to-present-at-2011-bio-international-convention https://www.titanpharm.com/news/press-releases/detail/73/titan-pharmaceuticals-provides-additional-details-on-confirmatory-phase-3-study-of-probuphine https://www.titanpharm.com/news/press-releases/detail/72/titan-pharmaceuticals-provides-update-on-confirmatory-phase-3-study-of-probuphine https://www.titanpharm.com/news/press-releases/detail/71/titan-pharmaceuticals-announces-first-quarter-2011-financial-results https://www.titanpharm.com/news/press-releases/detail/70/titan-pharmaceuticals-reports-fourth-quarter-and-full-year-2010-financial-results https://www.titanpharm.com/news/press-releases/detail/69/titan-pharmaceuticals-enters-into-a-20-million-credit-facility-with-deerfield-management https://www.titanpharm.com/news/press-releases/detail/68/titan-reports-fourth-quarter-2010-fanapt-royalty https://www.titanpharm.com/news/press-releases/detail/67/titan-pharmaceuticals-presents-phase-3-probuphine-data-at-society-for-neuroscience-annual-meeting https://www.titanpharm.com/news/press-releases/detail/66/titan-pharmaceuticals-announces-third-quarter-2010-financial-results https://www.titanpharm.com/news/press-releases/detail/65/titan-reports-third-quarter-2010-fanapt-royalty https://www.titanpharm.com/news/press-releases/detail/64/titan-pharmaceuticals-announces-journal-of-the-american-medical-association-publication-of-phase-3-probuphine-data https://www.titanpharm.com/news/press-releases/detail/63/titan-pharmaceuticals-completes-5-million-loan https://www.titanpharm.com/news/press-releases/detail/62/titan-reports-completion-of-patient-enrollment-in-phase-3-study-of-probuphine https://www.titanpharm.com/news/press-releases/detail/61/titan-pharmaceuticals-announces-second-quarter-2010-financial-results https://www.titanpharm.com/news/press-releases/detail/60/titan-reports-patient-enrollment-in-phase-iii-study-of-probuphine-is-ahead-of-schedule https://www.titanpharm.com/news/press-releases/detail/59/titan-receives-sbir-grant-to-investigate-long-term-treatment-for-parkinsons-disease https://www.titanpharm.com/news/press-releases/detail/58/titan-reports-second-quarter-2010-fanapt-royalty https://www.titanpharm.com/news/press-releases/detail/57/probuphiner-patent-issued-by-the-u-s-patent-and-trademark-office https://www.titanpharm.com/news/press-releases/detail/56/titan-stock-commences-trading-on-the-otcbb https://www.titanpharm.com/news/press-releases/detail/55/titan-pharmaceuticals-announces-first-quarter-2010-financial-results https://www.titanpharm.com/news/press-releases/detail/54/titan-announces-completion-of-re-registration-of-the-company-with-the-securities-and-exchange-commission https://www.titanpharm.com/news/press-releases/detail/53/titan-provides-estimate-of-upcoming-royalty-payment https://www.titanpharm.com/news/press-releases/detail/52/titan-initiates-confirmatory-phase-3-study-of-probuphiner-in-the-treatment-of-opioid-addiction https://www.titanpharm.com/news/press-releases/detail/51/titan-pharmaceuticals-to-present-at-the-12th-annual-bio-ceo-investor-conference https://www.titanpharm.com/news/press-releases/detail/50/titan-pharmaceuticals-files-form-10-for-re-registration-of-the-company-with-the-securities-and-exchange-commission https://www.titanpharm.com/news/press-releases/detail/49/titan-pharmaceuticals-to-receive-3-million-loan https://www.titanpharm.com/news/press-releases/detail/48/titan-receives-notice-of-allowance-for-probuphiner-patent-application-in-the-treatment-of-opiate-addiction https://www.titanpharm.com/news/press-releases/detail/47/novartis-pharma-acquires-exclusive-rights-from-vanda-pharmaceuticals-for-commercialization-of-fanapttm-in-the-united-states-and-canada https://www.titanpharm.com/news/press-releases/detail/46/titan-announces-award-of-nih-grant-for-probuphiner-clinical-development https://www.titanpharm.com/news/press-releases/detail/45/titan-re-engages-key-executives https://www.titanpharm.com/news/press-releases/detail/44/titan-announces-fda-approval-of-fanapttm-iloperidone-for-the-treatment-of-schizophrenia